RxDoctor Payments Data

James Melott, MD

Family Medicine · San Angelo, TXNPI 1780680082

Payments from drug & device makers

$1,750in general payments, 2019–2025

Across 115 payments — averaging $15.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$411
  • Johnson & Johnson$291
  • Amgen$241
  • Novo Nordisk$161
  • GSK$128
  • Astellas Pharma US Inc$121
  • plus $398 from 14 others

What the payments were for

  • Food & beverage$1,749100%
  • Education$10%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,750 in reported general payments places this provider in the 70th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$252,452
Medicare patients
377
Services billed
4,437

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide120$148,187
MounjaroTirzepatide63$90,478
RybelsusSemaglutide36$62,929
FarxigaDapagliflozin Propanediol60$54,070
EliquisApixaban55$50,943
Trelegy ElliptaFluticasone/Umeclidin/Vilanter47$48,442
XareltoRivaroxaban27$29,113
MyrbetriqMirabegron52$27,970
TrulicityDulaglutide21$25,829
JanuviaSitagliptin Phosphate12$15,945
Lantus SolostarInsulin Glargine,hum.Rec.Anlog32$10,509
Janumet XrSitagliptin Phos/Metformin Hcl15$9,121
Combivent RespimatIpratropium/Albuterol Sulfate13$7,537
Mirabegron ErMirabegron14$6,751
Fluticasone-SalmeterolFluticasone Propion/Salmeterol26$6,616

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$161$211,116156 claims
Lilly USA, LLCMounjaro, Trulicity$41$116,30784 claims
GSKTrelegy Ellipta, Anoro Ellipta$128$54,22759 claims
AstraZenecaFarxiga$11$54,07060 claims
Johnson & JohnsonXarelto$291$29,11327 claims
Astellas Pharma US IncMyrbetriq$121$27,97052 claims
MerckJanuvia, Janumet Xr$66$25,06627 claims
Boehringer IngelheimCombivent Respimat$56$7,53713 claims
AbbVieSynthroid$411$2,42974 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,760 family medicine providers in Texas.

Other family medicine in San Angelo

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →